Adam Keeney
Head of Corporate DevelopmentBiogen
M&AView Profile →Senior Vice President, Chief Strategy and M&A Officer · Quest Diagnostics
Benjamin Beauvalot is senior vice president and chief strategy and M&A officer of Quest Diagnostics. His career spans strategy, corporate development and business operations in pharmaceutical services, biotechnology and genomics.
Last reviewed: Nov 2, 2026
Senior Vice President, Chief Strategy and M&A Officer
Quest Diagnostics
Last Reviewed: November 2, 2026
Benjamin Beauvalot is senior vice president and chief strategy and M&A officer of Quest Diagnostics. His career spans strategy, corporate development and business operations in pharmaceutical services, biotechnology and genomics.
Beauvalot served as vice president of strategy at specialty-pharmaceutical company Banner Life Sciences. At Patheon, a pharmaceutical services provider, his positions included vice president of strategy and corporate development and vice president of global business operations. He held those assignments before Thermo Fisher Scientific acquired Patheon in 2017.
He subsequently worked at Danaher in strategy and mergers and acquisitions. His responsibilities included serving as vice president and head of business development and strategy for the company’s biotechnology and genomics business areas.
Quest announced his arrival in February 2026 as senior vice president and chief strategy and M&A officer. Reporting to chairman and CEO Jim Davis, he joined the executive leadership team with responsibility for growth strategy, acquisitions, strategic partnerships and integration. He succeeded Dermot Shorten, whose retirement Quest announced for the second quarter of 2026.
Beauvalot earned a degree in management and business administration at IPAG in Paris.